DrugPatentWatch Database Preview
Drugs in Development Information for DAS181
Email this page to a colleague
What is the drug development status for DAS181?
DAS181 is an investigational drug.
There have been 14 clinical trials for DAS181.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 28th 2019.
The most common disease conditions in clinical trials are Influenza, Human, Paramyxoviridae Infections, and Infection. The leading clinical trial sponsors are Ansun Biopharma, Inc., National Institute of Allergy and Infectious Diseases (NIAID), and National Institutes of Health (NIH).
There are three US patents protecting this investigational drug and thirty-nine international patents.
Summary for DAS181
| US Patents | 3 |
| International Patents | 39 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-02-28) |
| Vendors | 0 |
Recent Clinical Trials for DAS181
| Title | Sponsor | Phase |
|---|---|---|
| DAS181 for STOP COVID-19 | Ansun Biopharma, Inc. | Phase 2/Phase 3 |
| DAS181 for COVID-19: Compassionate Use | Ansun Biopharma, Inc. | N/A |
| DAS181 for COVID-19: Compassionate Use | Renmin Hospital of Wuhan University | N/A |
Clinical Trial Summary for DAS181
Top disease conditions for DAS181
Top clinical trial sponsors for DAS181
US Patents for DAS181
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| DAS181 | Get Started Free | Treatment of infection by human enterovirus D68 | Ansun Biopharma, Inc. (San Diego, CA) | Get Started Free |
| DAS181 | Get Started Free | 2'-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (Foster City, CA) | Get Started Free |
| DAS181 | Get Started Free | Microparticle formulations for delivery to the lower and central respiratory tract and methods of manufacture | Ansun Biopharma, Inc. (San Diego, CA) | Get Started Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for DAS181
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| DAS181 | World Intellectual Property Organization (WIPO) | WO2016044656 | 2034-09-17 | Get Started Free |
| DAS181 | Australia | AU2013232378 | 2032-03-13 | Get Started Free |
| DAS181 | Australia | AU2017279590 | 2032-03-13 | Get Started Free |
| DAS181 | Brazil | BR122016003311 | 2032-03-13 | Get Started Free |
| DAS181 | Canada | CA2866381 | 2032-03-13 | Get Started Free |
| DAS181 | China | CN104185638 | 2032-03-13 | Get Started Free |
| DAS181 | China | CN106749272 | 2032-03-13 | Get Started Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
